Mersana Therapeutics Inc (MRSN)
2.555
-0.06
(-2.11%)
USD |
NASDAQ |
May 15, 15:33
Mersana Therapeutics Revenue (Quarterly): 9.245M for March 31, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 9.245M |
December 31, 2023 | 10.70M |
September 30, 2023 | 7.698M |
June 30, 2023 | 10.65M |
March 31, 2023 | 7.802M |
December 31, 2022 | 14.69M |
September 30, 2022 | 5.573M |
June 30, 2022 | 4.284M |
March 31, 2022 | 2.036M |
December 31, 2021 | 0.011M |
September 30, 2021 | 0.011M |
June 30, 2021 | 0.011M |
March 31, 2021 | 0.011M |
December 31, 2020 | 0.011M |
September 30, 2020 | 0.011M |
June 30, 2020 | 0.796M |
March 31, 2020 | 0.011M |
Date | Value |
---|---|
December 31, 2019 | 0.042M |
September 30, 2019 | 0.844M |
June 30, 2019 | 0.202M |
March 31, 2019 | 41.04M |
December 31, 2018 | 1.189M |
September 30, 2018 | 2.151M |
June 30, 2018 | 4.191M |
March 31, 2018 | 3.064M |
December 31, 2017 | 3.261M |
September 30, 2017 | 6.267M |
June 30, 2017 | 3.727M |
March 31, 2017 | 4.29M |
December 31, 2016 | 12.00M |
September 30, 2016 | 3.262M |
June 30, 2016 | 6.215M |
March 31, 2016 | 3.697M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.011M
Minimum
Mar 2020
14.69M
Maximum
Dec 2022
3.732M
Average
0.82M
Median
Revenue (Quarterly) Benchmarks
Amicus Therapeutics Inc | 110.40M |
Geron Corp | 0.304M |
Insmed Inc | 75.50M |
Altimmune Inc | 0.037M |
InfuSystems Holdings Inc | 32.00M |
Revenue (Quarterly) Related Metrics
Net Income (Quarterly) | -19.31M |
Total Expenses (Quarterly) | 30.25M |
EPS Diluted (Quarterly) | -0.16 |
Enterprise Value | 161.52M |
Profit Margin (Quarterly) | -208.8% |
Earnings Yield | -44.62% |
Normalized Earnings Yield | -41.79 |